PMID- 29852745
OWN - NLM
STAT- MEDLINE
DCOM- 20180716
LR  - 20190221
IS  - 1943-572X (Electronic)
IS  - 0003-4894 (Linking)
VI  - 127
IP  - 7
DP  - 2018 Jul
TI  - Intravenous 5-Fluorouracil in Patients With Advanced Squamous Cell Carcinoma: A 
      Retrospective Study.
PG  - 456-462
LID - 10.1177/0003489418778066 [doi]
AB  - OBJECTIVES: In the EXTREME trial, a combination of cisplatin or carboplatin plus 
      5-fluorouracil (5-FU) and cetuximab was superior to cisplatin/carboplatin plus 
      5-FU for first-line treatment of recurrent or metastatic head and neck squamous 
      cell carcinoma (HNSCC). With the aim of improving fluoropyrimidine-related 
      tolerance without decreasing its efficacy, the safety and efficacy of carboplatin 
      plus the oral fluoropyrimidine tegafur and cetuximab were investigated. METHODS: 
      A retrospective analysis of 104 patients with recurrent or metastatic HNSCC was 
      conducted. Patients were treated with carboplatin (area under the curve: 5 
      mg/mL/min) on day 1, oral tegafur (250 mg/m(2) twice daily) for 21 consecutive 
      days, and cetuximab (400 mg/m(2) as an initial 2-hour intravenous infusion, then 
      250 mg/m(2) as a 1-hour weekly infusion for 3 weeks) for </=6 cycles. Patients who 
      responded to the therapy then received weekly cetuximab maintenance therapy. 
      RESULTS: Treatment was well tolerated with a high level of compliance (relative 
      dose intensity: 96%, 88%, and 81% for carboplatin, tegafur, and cetuximab, 
      respectively). Grade 3-4 adverse events (AEs) were observed in 38% of patients 
      (skin reactions in 17% of patients, anemia 4%, and neutropenia 3%). Grade 1-2 AEs 
      included skin reactions (52% of patients), hypomagnesemia (20%), asthenia (19%), 
      and anemia (13%). No venous thrombosis related to chemotherapy perfusion was 
      observed. Over a median follow-up of 21 months, the median overall and 
      progression-free survival were 11 and 6 months, respectively, and the overall 
      response rate was 35%. CONCLUSIONS: Carboplatin plus oral tegafur and cetuximab 
      is a safe, well-tolerated first-line therapy for recurrent or metastatic HNSCC.
FAU - Buxo, Elvira
AU  - Buxo E
AD  - 1 Medical Oncology Departments, Hospital Clinic of Barcelona, University of 
      Barcelona, Institut D'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), 
      Barcelona, Spain.
FAU - Sosa, Aaron
AU  - Sosa A
AD  - 1 Medical Oncology Departments, Hospital Clinic of Barcelona, University of 
      Barcelona, Institut D'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), 
      Barcelona, Spain.
FAU - Reig, Oscar
AU  - Reig O
AD  - 1 Medical Oncology Departments, Hospital Clinic of Barcelona, University of 
      Barcelona, Institut D'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), 
      Barcelona, Spain.
FAU - Victoria, Ivan
AU  - Victoria I
AD  - 1 Medical Oncology Departments, Hospital Clinic of Barcelona, University of 
      Barcelona, Institut D'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), 
      Barcelona, Spain.
FAU - Caballero, Miguel
AU  - Caballero M
AUID- ORCID: 0000-0002-6105-3750
AD  - 2 Otorhinolaryngology Departments, Hospital Clinic of Barcelona, University of 
      Barcelona, Institut D'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), 
      Barcelona, Spain.
AD  - 3 AMiQ-Otorhinolaryngology, Hospital Dexeus, Barcelona, Spain.
FAU - Grau, Juan Jose
AU  - Grau JJ
AD  - 1 Medical Oncology Departments, Hospital Clinic of Barcelona, University of 
      Barcelona, Institut D'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), 
      Barcelona, Spain.
FAU - Garcia-Morillo, Marcial
AU  - Garcia-Morillo M
AD  - 1 Medical Oncology Departments, Hospital Clinic of Barcelona, University of 
      Barcelona, Institut D'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), 
      Barcelona, Spain.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20180601
PL  - United States
TA  - Ann Otol Rhinol Laryngol
JT  - The Annals of otology, rhinology, and laryngology
JID - 0407300
RN  - 0 (Immunosuppressive Agents)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - Aged
MH  - Carcinoma, Squamous Cell/diagnosis/*drug therapy/mortality
MH  - Disease-Free Survival
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Fluorouracil/*administration & dosage
MH  - Follow-Up Studies
MH  - Head and Neck Neoplasms/diagnosis/*drug therapy/mortality
MH  - Humans
MH  - Immunosuppressive Agents/administration & dosage
MH  - Infusions, Intravenous
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Retrospective Studies
MH  - Spain/epidemiology
MH  - Squamous Cell Carcinoma of Head and Neck
MH  - Survival Rate/trends
MH  - Treatment Outcome
OTO - NOTNLM
OT  - carboplatin
OT  - cetuximab
OT  - oral fluoropyrimidine
OT  - squamous cell carcinoma
OT  - tegafur
EDAT- 2018/06/02 06:00
MHDA- 2018/07/17 06:00
CRDT- 2018/06/02 06:00
PHST- 2018/06/02 06:00 [pubmed]
PHST- 2018/07/17 06:00 [medline]
PHST- 2018/06/02 06:00 [entrez]
AID - 10.1177/0003489418778066 [doi]
PST - ppublish
SO  - Ann Otol Rhinol Laryngol. 2018 Jul;127(7):456-462. doi: 10.1177/0003489418778066. 
      Epub 2018 Jun 1.